CVS · Cvs Health Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.43B | - | $102.87B | $98.92B | $94.59B | - | $95.43B | $91.23B | $88.44B | - |
| Cost of Revenue | $55.44B | - | $57.05B | $54.01B | $51.06B | - | $52.95B | $50.00B | $48.07B | - |
| Gross Profit | $44.98B | - | $45.83B | $44.91B | $43.53B | - | $42.48B | $41.24B | $40.36B | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $95.75B | - | $106.08B | $96.53B | $91.21B | - | $94.60B | $88.19B | $86.17B | - |
| D&A | $1.11B | - | $1.16B | $1.17B | $1.15B | - | - | - | $1.14B | - |
| Operating Income | $4.68B | - | ($3.21B) | $2.38B | $3.37B | - | $832.00M | $3.04B | $2.27B | - |
| Interest Expense | $774.00M | - | $784.00M | $763.00M | $716.00M | - | $752.00M | $732.00M | $716.00M | - |
| Income Tax | $981.00M | - | $508.00M | $634.00M | $835.00M | - | $34.00M | $569.00M | $456.00M | - |
| Net Income | $2.94B | - | ($3.98B) | $1.02B | $1.78B | - | $87.00M | $1.77B | $1.11B | - |
| EPS - Basic | $2.31 | - | ($3.13) | $0.81 | $1.41 | - | $0.07 | $1.41 | $0.88 | - |
| EPS - Diluted | $2.30 | - | ($3.13) | $0.80 | $1.41 | - | $0.07 | $1.41 | $0.88 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.54B | $8.45B | $9.10B | $11.79B | $10.08B | $8.59B | $6.88B | $12.51B | $9.80B | $8.20B |
| Accounts Receivable | $40.99B | $39.78B | $43.86B | $40.65B | $39.63B | $36.47B | $36.18B | $32.38B | $32.22B | $35.23B |
| Inventory | $17.77B | $19.25B | $18.96B | $17.45B | $17.39B | $18.11B | $17.65B | $16.07B | $16.35B | $18.02B |
| Accounts Payable | $16.92B | $17.64B | $17.76B | $17.26B | $16.53B | $15.89B | $15.71B | $14.42B | $13.72B | $14.90B |
| Current Assets | $74.82B | $74.71B | $77.11B | $75.65B | $73.19B | $68.64B | $67.34B | $69.95B | $67.47B | $67.86B |
| Total Assets | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B | $253.22B | $252.43B | $252.48B | $249.74B | $249.73B |
| Current Liabilities | $86.41B | $88.69B | $92.69B | $94.16B | $88.96B | $84.61B | $84.63B | $81.39B | $83.32B | $79.19B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $175.34B | $178.16B | $182.22B | $180.79B | $178.47B | $177.49B | $177.32B | $177.37B | $175.59B | $173.09B |
| Stockholders' Equity | $77.46B | $75.21B | $72.93B | $77.38B | $76.93B | $75.56B | $74.94B | $74.93B | $73.97B | $76.46B |
| Retained Earnings | $63.28B | $61.20B | $59.11B | $63.94B | $63.77B | $62.84B | $62.04B | $62.80B | $61.87B | $61.60B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.25B | - | - | - | $4.56B | - | - | - | $4.90B | - |
| Investing Cash Flow | ($874.00M) | - | - | - | ($762.00M) | - | - | - | ($2.09B) | - |
| Financing Cash Flow | ($2.32B) | - | - | - | ($2.33B) | - | - | - | ($1.23B) | - |
| CapEx | $849.00M | - | - | - | $743.00M | - | - | - | $705.00M | - |
| Free Cash Flow | $3.40B | - | - | - | $3.81B | - | - | - | $4.20B | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.8% | - | 44.5% | 45.4% | 46.0% | - | 44.5% | 45.2% | 45.6% | - |
| Operating margin | 4.7% | - | -3.1% | 2.4% | 3.6% | - | 0.9% | 3.3% | 2.6% | - |
| EBITDA margin | 5.8% | - | -2.0% | 3.6% | 4.8% | - | - | - | 3.9% | - |
| Net margin | 2.9% | - | -3.9% | 1.0% | 1.9% | - | 0.1% | 1.9% | 1.3% | - |
| Free cash flow margin | 3.4% | - | - | - | 4.0% | - | - | - | 4.7% | - |
| FCF / Net income | 1.16 | - | - | - | 2.14 | - | - | - | 3.77 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 25.0% | - | - | 38.3% | 31.9% | - | 28.1% | 24.3% | 29.1% | - |
| Return on assets | 1.2% | - | -1.6% | 0.4% | 0.7% | - | 0.0% | 0.7% | 0.4% | - |
| Return on equity | 3.8% | - | -5.5% | 1.3% | 2.3% | - | 0.1% | 2.4% | 1.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.87 | 0.84 | 0.83 | 0.80 | 0.82 | 0.81 | 0.80 | 0.86 | 0.81 | 0.86 |
| Quick ratio | 0.66 | 0.63 | 0.63 | 0.62 | 0.63 | 0.60 | 0.59 | 0.66 | 0.61 | 0.63 |
| Cash ratio | 0.11 | 0.10 | 0.10 | 0.13 | 0.11 | 0.10 | 0.08 | 0.15 | 0.12 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 6.0x | - | -4.1x | 3.1x | 4.7x | - | 1.1x | 4.2x | 3.2x | - |
| Equity multiplier | 3.27 | 3.37 | 3.50 | 3.34 | 3.32 | 3.35 | 3.37 | 3.37 | 3.38 | 3.27 |
| Liabilities / Assets | 0.69 | 0.70 | 0.71 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.69 |
| Efficiency | ||||||||||
| Asset turnover | 0.40 | - | 0.40 | 0.38 | 0.37 | - | 0.38 | 0.36 | 0.35 | - |
| Inventory turnover | 3.12 | - | 3.01 | 3.10 | 2.94 | - | 3.00 | 3.11 | 2.94 | - |
| Days sales outstanding | 149d | - | 156d | 150d | 153d | - | 138d | 130d | 133d | - |
| Days inventory outstanding | 117d | - | 121d | 118d | 124d | - | 122d | 117d | 124d | - |
| Days payable outstanding | 111d | - | 114d | 117d | 118d | - | 108d | 105d | 104d | - |
| Cash conversion cycle | 155d | - | 163d | 151d | 159d | - | 152d | 142d | 153d | - |
| Valuation | ||||||||||
| P / E | 31.2x | - | - | 86.2x | 48.0x | - | 898.3x | 41.9x | 90.6x | - |
| P / B | 1.2x | - | 1.3x | 1.1x | 1.1x | - | 1.1x | 1.0x | 1.4x | - |
| P / S | 0.9x | - | 0.9x | 0.9x | 0.9x | - | 0.8x | 0.8x | 1.1x | - |
| EV / EBITDA | 14.2x | - | - | 21.3x | 16.7x | - | - | - | 26.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 6.2% | - | 7.8% | 8.4% | 7.0% | - | 6.3% | 2.6% | 3.7% | - |
| Revenue CAGR (3y) | 5.6% | - | 8.2% | 7.0% | 7.2% | - | 8.9% | 7.9% | 8.6% | - |
| Revenue CAGR (5y) | 7.8% | - | 8.9% | 8.6% | 7.2% | - | 8.0% | 7.5% | 7.5% | - |
| Gross profit growth (YoY) | 3.3% | - | 7.9% | 8.9% | 7.8% | - | 21.1% | 16.5% | 19.3% | - |
| Operating income growth (YoY) | 38.7% | - | - | -21.8% | 48.6% | - | -77.5% | -5.8% | -34.1% | - |
| Net income growth (YoY) | 65.4% | - | - | -42.3% | 59.8% | - | -96.2% | -6.9% | -47.9% | - |
| EPS growth (YoY) | 63.1% | - | - | -43.3% | 60.2% | - | -96.0% | -4.7% | -46.7% | - |
| EPS CAGR (3y) | 11.7% | - | - | -28.9% | -6.8% | - | -61.2% | -12.4% | -19.4% | - |
| EPS CAGR (5y) | 6.5% | - | - | -18.8% | -1.6% | - | -43.1% | -1.1% | -4.2% | - |
| FCF growth (YoY) | -10.8% | - | - | - | -9.2% | - | - | - | -35.0% | - |
| FCF CAGR (5y) | 10.5% | - | - | - | 8.3% | - | - | - | 27.8% | - |
| Book value growth (YoY) | 0.7% | -0.5% | -2.7% | 3.3% | 4.0% | -1.2% | 0.8% | 3.0% | 3.6% | 7.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$473.63B totalHealth Services Segment$190.43B · 40.2%
Health Care Benefits Segment$143.35B · 30.3%
Pharmacy And Consumer Health Segment$139.37B · 29.4%
Corporate And Other Segment$484.00M · 0.1%
Product / service
$265.08B totalProduct$249.91B · 94.3%
Service$15.18B · 5.7%
Peer comparison
Same SIC group: Retail-Drug Stores and Proprietary Stores
Comparing CVS HEALTH Corp against the 5 most active filers in the same SIC group.
Dividends
$2.66/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| Apr 23, 2026 | $0.6650 |
| Jan 22, 2026 | $0.6650 |
| Oct 23, 2025 | $0.6650 |
| Jul 22, 2025 | $0.6650 |
| Apr 22, 2025 | $0.6650 |
| Jan 23, 2025 | $0.6650 |
| Oct 21, 2024 | $0.6650 |
| Jul 22, 2024 | $0.6650 |
| Apr 19, 2024 | $0.6650 |
| Jan 19, 2024 | $0.6650 |
| Oct 19, 2023 | $0.6050 |
| Jul 20, 2023 | $0.6050 |
| Apr 20, 2023 | $0.6050 |
| Jan 19, 2023 | $0.6050 |
| Oct 20, 2022 | $0.5500 |
| Jul 21, 2022 | $0.5500 |
| Apr 21, 2022 | $0.5500 |
| Jan 20, 2022 | $0.5500 |
| Oct 21, 2021 | $0.5000 |
| Jul 22, 2021 | $0.5000 |
| Apr 22, 2021 | $0.5000 |
| Jan 21, 2021 | $0.5000 |
| Oct 21, 2020 | $0.5000 |
| Jul 22, 2020 | $0.5000 |